MindWalk Holdings (HYFT) Receivables (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Receivables of $1.8 million for Q2 2026, down 36.2% year-over-year from $2.9 million in Q2 2025, and up 35.97% quarter-over-quarter from $1.4 million in Q1 2026.
Analysis
MindWalk Holdings (HYFT) Receivables (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Receivables for 7 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables fell 36.2% year-over-year to $1.8 million; the TTM figure through Apr 2026 stood at $1.8 million (down 36.2% YoY), while the FY2026 annual figure was $1.8 million, down 37.55% from the prior year.
- Receivables advanced to $1.8 million in Q2 2026 per HYFT's latest filing, from $1.4 million in the prior quarter.
- Across five years, Receivables topped out at $3.0 million in Q4 2024 and bottomed at $1.3 million in Q3 2025.
- Historically, Receivables has averaged $2.2 million across 5 years, with a median of $2.3 million in 2024.
- Annual changes were most pronounced in 2022 — Receivables soared 40.28% — and 2026, when it slumped 46.58%.
- MindWalk Holdings' Receivables stood at $2.4 million in 2022, then climbed by 9.79% to $2.7 million in 2023, then increased by 12.63% to $3.0 million in 2024, then retreated by 25.21% to $2.2 million in 2025, then retreated by 17.92% to $1.8 million in 2026.
- Business Quant data shows HYFT's Receivables at $1.8 million in Q2 2026, $1.4 million in Q1 2026, and $2.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - | - |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 215.33 Mn |
| 10 | MindWalk Holdings | 61.22 Mn | 52.95 Mn | 1.82 Mn | 2.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 2.27 Mn |
| Jan 31, 2026 | 2.03 Mn |
| Oct 31, 2025 | 2.91 Mn |
| Jul 31, 2025 | 1.71 Mn |
| Apr 30, 2025 | 3.28 Mn |
| Jan 31, 2025 | 3.30 Mn |
| Oct 31, 2024 | 3.69 Mn |
| Jul 31, 2024 | 2.33 Mn |
| Apr 30, 2024 | 3.00 Mn |
| Jan 31, 2024 | 3.02 Mn |
| Oct 31, 2023 | 3.45 Mn |
| Jul 31, 2023 | 3.47 Mn |
| Apr 30, 2023 | 2.87 Mn |
| Jan 31, 2023 | 2.17 Mn |
| Oct 31, 2022 | 2.99 Mn |
| Jul 31, 2022 | 2.68 Mn |
| Apr 30, 2022 | 2.47 Mn |
| Jan 31, 2022 | 2.65 Mn |
| Oct 31, 2021 | 2.24 Mn |
| Jul 31, 2021 | 2.79 Mn |